Pilot study of continuous low-dose 5-fluorouracil and cisplatin (FP regimen) for the treatment of metastatic breast cancer

被引：7

作者：

Yamada Y. ^{[1
]}

Aiba K. ^{[2
]}

Horikosi N. ^{[2
]}

Hanai M. ^{[2
]}

Uno S. ^{[2
]}

Osawa H. ^{[2
]}

Mizunuma N. ^{[2
]}

Takahashi S. ^{[2
]}

Ito Y. ^{[2
]}

机构：

[1] Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku

[2] Department of Medical Oncology, Cancer Institute Hospital, Tokyo

来源：

International Journal of Clinical Oncology | 2000年 / 5卷 / 1期

关键词：

5-Fluorouracil; Anthracycline-; resistant; Breast cancer; Cisplatin; Low-dose FP;

D O I：

10.1007/s101470050004

中图分类号：

学科分类号：

摘要：

Background. The effect of low-dose 5-fluorouracil (FU) and cisplatin therapy (FP regimen) against metastatic breast cancer was investigated. Methods. A pilot study of the FP regimen was performed in 11 patients with metastatic breast carcinoma who had previously received chemotherapy, including adriamycin, and/or hormonal therapy. Their median age was 56 years (range, 48-72 years). Visceral metastases were present in all patients. FU, at a dose of 170mg/m2 per day, was administered for 28 days by continuous intravenous infusion. Cisplatin (7mg/m2 per day) was given intravenously on days 1-5, 8-12, 15-19, and 22-26. After a 2-week interval, this treatment was repeated. Results. Of the 11 patients assessable for tumor response to the FP regimen, 4 patients (36%; 95% confidence intervals [CI], 8%-64%) achieved an objective response, with 1 showing a complete response and 3 showing a partial response. Median time to progression was 6.5 months (range, 4-25 months). The median survival time from the initiation of the FP regimen was 11 months (range, 3-25 months). Gastrointestinal and hematologic toxicity was mild. Conclusion. The FP regimen is promising for and has acceptable tolerance in patients with metastatic breast carcinoma refractory to previous anthracycline-containing chemotherapy.

引用

页码：18 / 21

页数：3

共 15 条

[1]

MacMillan, W.E., Wobery, W.H., Welling, P.G., Pharmacokinetics of 5-fluorouracil in humans (1978) Cancer Res, 38, pp. 3479-3482

[2]

Schackney, S.E., Cell kinetics and cancer chemotherapy (1985) Medical Oncology, pp. 41-60. , Calabresi P, Schein PS, Rosenberg SA (eds) McMillan, New York

[3]

Tsujinaka, T., Kido, Y., Shiozaki, H., Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer (1992) Cancer, 70, pp. 2761-2765

[4]

Lokich, J.J., Ahlgren, J.D., Gullo, J.J., A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study (1989) J Clin Oncol, 17, pp. 425-432

[5]

Sledge, G.W., Loehler, P.J., Roth, B.J., Einhorn, L.H., Cisplatin as first-line therapy for metastatic breast cancer (1988) J Clin Oncol, 6, pp. 1811-1814

[6]

Kolaric, K., Roth, A., Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer (1983) Cancer Chemother Pharmacol, 11, pp. 108-112

[7]

Yap, H.Y., Salem, P., Hortobagyi, G.N., Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer (1978) Cancer Treat Rep, 62, pp. 405-408

[8]

Shirasaka, T., Shimamoto, Y., Ohshima, H., Metabolic basis of the synergistic antitumor activites of 5-fluorouracil and cisplatin in rodent tumor models in vivo (1993) Cancer Chemother Pharmacol, 32, pp. 167-172

[9]

Scanlon, K.J., Newman, E.M., Lu, Y., Priest, D.G., Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells (1986) Proc Natl Acad Sci USA, 83, pp. 8923-8925

[10]

Chung, Y.S., Yamashita, Y., Inoue, T., Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma (1997) Cancer, 80, pp. 1-7

← 1 2 →